en Cellular and molecular Neuroscience Cellular and molecular Neuroscience Original Original <p dir="ltr" style="text-align: justify;"><strong>Introduction: </strong>Studies suggest that ATP-sensitive potassium (KATP) channels are a potential pharmacotherapeutic target for neuroprotection in neurodegenerative diseases. The current study aimed at evaluating the effect of pretreatment with glibenclamide (Glib) and B vitamins supplement on the severity of behavioral symptoms in 6-hydroxydopamine (OHDA)-induced Parkinsonism. Also malondialdehyde (MDA) concentration was measured in the blood and brain suspensions to find probable neuroprotective mechanism of Glib.<br> <strong>Methods:</strong> The 6-OHDA was injected into striatum of rats by stereotaxic surgery. Treatment with Glib and B vitamins was started before the surgery and continued up to 3 weeks after that. Development and severity of Parkinsonism were evaluated by conventional behavioral tests. MDA values were measured spectrophotometrically using thiobarbituric acid and MDA standard curve.<br> <strong>Results:</strong> Pretreatments with Glib, at both doses of 1 and 5 mg/kg or B vitamins significantly ameliorated severity of the behavioral symptoms. Pretreatment with a combination of Glib and B vitamins was more effective than pretreatment with Glib or B vitamins alone. Also, pretreatment with B vitamins, Glib, or a combination of them reduced MDA concentration in the brain suspensions. Decrease in MDA concentration in the group of rats that received a combination of B vitamins and Glib was more prominent than that of the Glib groups.&nbsp;<br> <strong>Conclusion:</strong> As severity of the behavioral symptoms in the 6-OHDA-induced Parkinsonism reflects the degree of the lesion in Substantia Nigra (SN) dopaminergic neurons, it is suggested that Glib pretreatment has neuroprotective effect against 6-OHDA-induced neurotoxicity. The current study data also showed that this effect may be mediated by antioxidant effect of Glib.&nbsp;</p> <p dir="ltr"></p> Parkinson disease, 6-Hydroxydopamine, Glibenclamide, B vitamins, Malondialdehyde 183 192 http://bcn.iums.ac.ir/browse.php?a_code=A-10-671-2&slc_lang=en&sid=1 Hossein Piri hosseinpiry@gmail.com 13700319475328460010320 13700319475328460010320 No Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. Hashem Haghdoost-Yazdi hhaghdoost@yahoo.com 13700319475328460010321 13700319475328460010321 Yes Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. Negin Fraidouni neginfraidouni@gmail.com 13700319475328460010322 13700319475328460010322 No Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Tahereh Dargahi tahere.dargahi@yahoo.com 13700319475328460010323 13700319475328460010323 No Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Mohamadhosein Yaghoubidoust mohamadhoseinyaghoubi@gmail.com 13700319475328460010324 13700319475328460010324 No Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Abbas Azadmehr azadmehr2010@gmail.com 13700319475328460010325 13700319475328460010325 No Department of Immunology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.